CELC
Celcuity Inc.
$88.28
-4.53%
$4.5B
No data for this timeframe.
Vol
Market Cap$4.5B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders7 funds
Inst. Value$511.3M
Inst. Activity4 buys / 2 sells
Insider Activity0B / 3S
Insider Net $-$3.9M
SEC Reports6
Press Releases4
Recent Activity
Jul 17, 2026
fda_pdufa
PDUFA: CELC — gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer — 2026-07-17
FDA target action date 2026-07-17 for CELC (Celcuity Inc.). Drug: gedatolisib. Indication: HR+/HER2-
Jun 5, 2026
SEC
Celcuity is issuing $500M of 0.250% convertible senior notes due 2032 (plus $75M over-allotment). Net proceeds of ~$484.
424B5 — Impact 6/10
Jun 3, 2026
SEC
Celcuity is offering $400M in convertible senior notes due 2032 (with a $60M over-allotment option). Proceeds will repay
424B5 — Impact 6/10
Jun 2, 2026
SEC
Celcuity announced detailed Phase 3 VIKTORIA-1 results showing its gedatolisib-triplet (gedatolisib + fulvestrant + palb
8-K — Impact 8/10
Jun 2, 2026
Insider
Laing Lance G. sold 1,000 shares
Chief Science Officer @ $0.00 ($0.00)
Jun 2, 2026
Insider
Laing Lance G. sold 1,000 shares
Chief Science Officer @ $9.89 ($9.9K)
May 19, 2026
Insider
Buller Richard E sold 1,029 shares
Director @ $0.00 ($0.00)
Inst.
BANK OF AMERICA CORP — ADD
977,118 shares ($97.5M)
Price Targets
$161.09
+82.5% upside
Strong Buy
Current $88.28
Low $145.00
Median $165.00
High $175.00
11 analysts
$145.00
$175.00
Analyst Ratings
7Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | Craig-Hallum | MAINTAIN | Buy → Buy |
| Jun 3, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Jun 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 15, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next FY | $0.74 ▲ +167.3% | $-1.34 — $2.82 | 121% YoY | 2 |
| Current Q | $-0.98 ▲ +3.0% | $-1.05 — $-0.91 | -5% YoY | 2 |
| Next Q | $-1.08 ▼ -6.4% | $-1.10 — $-1.07 | -39% YoY | 2 |
| Current FY | $-3.53 ▲ +6.6% | $-3.99 — $-3.07 | -10% YoY | 2 |
Latest Reports
MIXED
424B5
6/10
Celcuity is issuing $500M of 0.250% convertible senior notes due 2032 (plus $75M over-allotment). Net proceeds of ~$484.
Jun 5, 2026
MIXED
Press
6/10
Celcuity priced a $500M upsized convertible senior notes offering (0.250% coupon, due 2032), increased from $400M, with
Jun 4, 2026
BEARISH
424B5
6/10
Celcuity is offering $400M in convertible senior notes due 2032 (with a $60M over-allotment option). Proceeds will repay
Jun 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $227.4M | — |
| MORGAN STANLEY | $139.5M | ADD |
| BANK OF AMERICA CORP | $97.5M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $29.2M | NEW |
| WELLS FARGO & COMPANY/MN | $13.8M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Laing Lance | M | $0.00 |
| Jun 2, 2026 | Laing Lance | M | $9.9K |
| May 19, 2026 | Buller Richard | G | $0.00 |
| May 4, 2026 | Dalvey David | SELL | $3.5M |
| May 4, 2026 | Buller Richard | SELL | $176.6K |
7 institutional holders with $511.3M total value (5,126,127 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 4 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,279,433 | $227.4M | 44.5% | — |
| 2 | MORGAN STANLEY | 1,398,970 | $139.5M | 27.3% | ADD +92.9% |
| 3 | BANK OF AMERICA CORP /DE/ | 977,118 | $97.5M | 19.1% | ADD +81.1% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 292,315 | $29.2M | 5.7% | NEW |
| 5 | WELLS FARGO & COMPANY/MN | 138,435 | $13.8M | 2.7% | DOUBLED +520.0% |
| 6 | FMR LLC | 26,651 | $2.7M | 0.5% | DOUBLED +786.3% |
| 7 | NORGES BANK | 13,205 | $1.3M | 0.3% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 539,527 | 977,118 | +81.1% | $97.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 22,327 | 138,435 | +520.0% | $13.8M | 2025-Q4 |
| FMR LLC | DOUBLED | 3,007 | 26,651 | +786.3% | $2.7M | 2025-Q4 |
| NORGES BANK | NEW | — | 13,205 | — | $1.3M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 194,800 | 0 | -100.0% | $0.00 | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 62,779 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | ADD | 784,079 | 1,512,852 | +92.9% | $74.7M | 2025-Q3 |
| UBS Group AG | DOUBLED | 84,592 | 854,483 | +910.1% | $42.2M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 262,874 | 539,527 | +105.2% | $26.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 13,100 | 194,800 | +1387.0% | $9.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 62,779 | — | $3.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 15,012 | 22,327 | +48.7% | $1.1M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 13,100 | — | $174.9K | 2025-Q2 |
| FMR LLC | DOUBLED | 1,300 | 2,717 | +109.0% | $36.3K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 13,378 | 0 | -100.0% | $0.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 51,838 | 13,378 | -74.2% | $135.3K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,392,705 | 876,891 | -37.0% | $11.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 8,539 | 15,515 | +81.7% | $203.1K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 11,045 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | TRIM | 2,835,465 | 1,392,705 | -50.9% | $20.8M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 221,671 | — | $3.3M | 2024-Q3 |
5 unique insiders with 3 transactions. Net insider value: -$3.9M ($0.00 bought, $3.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Laing Lance G. | Chief Science Officer | M | 1,000 | $0.00 | $0.00 |
| Jun 2, 2026 | Laing Lance G. | Chief Science Officer | M | 1,000 | $9.89 | $9.9K |
| May 19, 2026 | Buller Richard E | Director | G | 1,029 | $0.00 | $0.00 |
| May 4, 2026 | Dalvey David | Director | SELL | 25,000 | $140.68 | $3.5M |
| May 4, 2026 | Buller Richard E | Director | SELL | 1,289 | $137.00 | $176.6K |
| May 4, 2026 | Buller Richard E | Director | M | 9,000 | $5.10 | $45.9K |
| May 4, 2026 | Buller Richard E | Director | M | 9,000 | $0.00 | $0.00 |
| Apr 9, 2026 | NIGON RICHARD | Director | G | 10,000 | $0.00 | $0.00 |
| Mar 31, 2026 | Buller Richard E | Director | M | 3,000 | $5.10 | $15.3K |
| Mar 31, 2026 | Buller Richard E | Director | SELL | 2,325 | $110.11 | $256.0K |
| Mar 31, 2026 | Buller Richard E | Director | M | 3,000 | $0.00 | $0.00 |
| Feb 11, 2026 | ROMP CHARLES R | Director | A | 215 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 2 neutral. Avg impact: 5.3/10.
MIXED
424B5
6/10
Celcuity is issuing $500M of 0.250% convertible senior notes due 2032 (plus $75M over-allotment). Ne
Jun 5, 2026
BEARISH
424B5
6/10
Celcuity is offering $400M in convertible senior notes due 2032 (with a $60M over-allotment option).
Jun 3, 2026
BULLISH
8-K
8/10
Celcuity announced detailed Phase 3 VIKTORIA-1 results showing its gedatolisib-triplet (gedatolisib
Jun 2, 2026
BULLISH
PRESS-RELEASE
7/10
Celcuity reported Q1 2026 GAAP EPS of -$0.97, a 9.0% miss vs consensus of -$0.89, with net loss wide
May 14, 2026
NEUTRAL
PRESS-RELEASE
3/10
Celcuity announced it will release Q1 2026 financial results on May 14, 2026, after market close. Th
May 7, 2026
NEUTRAL
144
2/10
Director David Dalvey filed a Form 144 notice of intent to sell 25,000 shares of Celcuity Inc. commo
May 4, 2026
MIXED
6/10
Celcuity priced a $500M upsized convertible senior notes offering (0.250% coupon, due 2032), increas
Jun 4, 2026
BEARISH
6/10
Celcuity announced a proposed $400M underwritten public offering of convertible senior notes due 203
Jun 3, 2026
BULLISH
8/10
Celcuity announced positive topline Phase 3 VIKTORIA-1 results for gedatolisib in PIK3CA mutant HR+/
May 1, 2026
MIXED
8/10
Celcuity announced strong clinical results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-
Mar 25, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 18 analysts: 7 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$161.09 mean target
+82.5% upside
Strong Buy (1.17)
$145.00 Low
$175.00 High
| Metric | Value |
|---|---|
| Current Price | $88.28 |
| Target Low | $145.00 |
| Target Mean | $161.09 |
| Target Median | $165.00 |
| Target High | $175.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.17) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next FY 2027-12-31 |
$0.74 | $-1.34 | $2.82 | 121.0% | +167.3% | 0↑ 1↓ | $0.4B | 810.1% | 2 |
| Current Q 2026-06-30 |
$-0.98 | $-1.05 | $-0.91 | -5.4% | +3.0% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-1.08 | $-1.10 | $-1.07 | -39.1% | -6.4% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-3.53 | $-3.99 | $-3.07 | -9.6% | +6.6% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.980 | |
| 7d ago | $-0.980 | |
| 30d ago | $-1.010 | +0.030 |
| 60d ago | $-1.010 | +0.030 |
| 90d ago | $-1.230 | +0.250 |
11 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 6 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Jun 3, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jun 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 15, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 15, 2026 | Needham | REITERATE | Buy | Buy |
| May 4, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| May 4, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| May 4, 2026 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| May 4, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 27, 2026 | Citizens | INITIATE | — | Market Outperform |
| Mar 26, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 17, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 10, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | Wells Fargo | INITIATE | — | Overweight |
| Dec 2, 2025 | Jefferies | MAINTAIN | Buy | Buy |
| Nov 18, 2025 | Wolfe Research | INITIATE | — | Outperform |
| Nov 17, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Nov 13, 2025 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Nov 13, 2025 | Stifel | MAINTAIN | Buy | Buy |
| Oct 22, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Oct 20, 2025 | Needham | REITERATE | Buy | Buy |
| Oct 3, 2025 | Needham | REITERATE | Buy | Buy |
| Sep 22, 2025 | Guggenheim | INITIATE | — | Buy |
| Aug 18, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 15, 2025 | Needham | MAINTAIN | Buy | Buy |
| Jul 28, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Jul 28, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jul 28, 2025 | Needham | REITERATE | Buy | Buy |
| Jun 30, 2025 | Needham | REITERATE | Buy | Buy |
| May 19, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 15, 2025 | Needham | REITERATE | Buy | Buy |
| Apr 11, 2025 | Needham | REITERATE | Buy | Buy |
| Apr 1, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 1, 2025 | Needham | REITERATE | Buy | Buy |
| Feb 6, 2025 | Needham | MAINTAIN | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 15, 2024 | Needham | REITERATE | Buy | Buy |
| Oct 7, 2024 | Stifel | MAINTAIN | Buy | Buy |
| Aug 26, 2024 | LifeSci Capital | INITIATE | — | Outperform |
| Aug 15, 2024 | Stifel | MAINTAIN | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 15, 2024 | Needham | REITERATE | Buy | Buy |
| Jul 22, 2024 | Leerink Partners | INITIATE | — | Outperform |
| May 31, 2024 | Needham | MAINTAIN | Buy | Buy |
| May 16, 2024 | Stifel | MAINTAIN | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 16, 2024 | Needham | REITERATE | Buy | Buy |
| Apr 12, 2024 | Needham | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Jan 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jul 17, 2026
fda_pdufa
PDUFA: CELC — gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer — 2026-07-17
FDA target action date 2026-07-17 for CELC (Celcuity Inc.). Drug: gedatolisib. Indication: HR+/HER2-/PIK3CA wild-type advanced breast cancer. FDA assi
Jun 5, 2026
short_volume
Short Volume: CELC — 59.0% short (0.5M / 0.8M)
Short: 478,048 | Exempt: 3,812 | TRF Vol: 810,851 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
offering
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
<p align="justify">MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biote
Jun 4, 2026
short_volume
Short Volume: CELC — 61.6% short (1.4M / 2.3M)
Short: 1,397,072 | Exempt: 0 | TRF Vol: 2,269,145 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
offering
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
<p align="justify">MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biote
Jun 3, 2026
short_volume
Short Volume: CELC — 77.7% short (1.6M / 2.1M)
Short: 1,611,314 | Exempt: 41,327 | TRF Vol: 2,072,627 | Short Ratio: 77.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
other
Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
<p>MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- <b> </b>Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the develo
Jun 2, 2026
short_volume
Short Volume: CELC — 55.3% short (1.5M / 2.7M)
Short: 1,511,098 | Exempt: 45,471 | TRF Vol: 2,730,176 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 28, 2026
other
Celcuity To Participate in Upcoming Investor Conferences
<p align="left">MINNEAPOLIS, May 28, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the de
May 15, 2026
short_volume
Short Volume: CELC — 74.8% short (0.4M / 0.6M)
Short: 415,165 | Exempt: 630 | TRF Vol: 554,826 | Short Ratio: 74.8% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
<p>MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of
May 14, 2026
other
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark O
May 14, 2026
earnings_calendar
CELC Q1 2026 Earnings After Market Close — 2026-05-14
May 14, 2026
short_volume
Short Volume: CELC — 71.8% short (0.6M / 0.8M)
Short: 606,732 | Exempt: 12 | TRF Vol: 844,831 | Short Ratio: 71.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
<p align="left">MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing developm
Apr 6, 2026
Clinical Trial
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Phase Phase 3 — ACTIVE_NOT_RECRUITING